Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students

Human and Experimental Toxicology

Volumn 23, Issue 3, 2004, Pages 149-156

  El Gohary, Mona ^a   Eid, Manal A ^b  

^a TANTA UNIVERSITY   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

Author keywords

Bhang; Fatty acid amide hydrolase; Immunotoxicity

Indexed keywords

CANNABINOID; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FATTY ACID AMIDASE; HYDROLASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGE DISTRIBUTION; ARTICLE; B LYMPHOCYTE; CANNABIS ADDICTION; COLLEGE STUDENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; EATING; HIGH SCHOOL; HUMAN; IMMUNE SYSTEM; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTOXICITY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SMOKING HABIT; SOCIAL STATUS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE SUBPOPULATION; TOXICITY TESTING; UNITED STATES;

CANNABIS; GLINUS;

EID: 8444244202     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327104ht426oa     Document Type: Article

References (37)

1. EL-Zeny A. The director of drug combat declares the war against bhang. J Neurol Sci 1999; 148: 79-86.
2. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-60.
3. Klein TW, Newton CA, Friedman H. Cannabinoids and the immune system. Off J Can Pain Soc 2001; 6: 95-101.
4. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 3: 313-19.
5. Guy A, Cabral GA. Marijuana and cannabinoids: effects on infections, immunity, and AIDS. J Cannabis Ther 2001; 1: 61-85.
6. National Toxicology Program NTP. Toxicology and carcinogenesis study. Natl Toxicol Program Tech Rep Ser 1996; 446: 1-317.
7. Roth MD, Balwin GC, Tashkin DP. Effects of delta-9-tetrahydrocannabinol on human immune function and host defence. Chem Phys Lipids 2002; 121: 229-39.
8. Schatz AR, Koh WS, Kaminiski NE. Delta 9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 1993; 26: 129-37.
9. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16: 209-19.
10. Condie R, Herring A, Koh WS, Lee M, Kaminski NE. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expressions in the murine T-cell line, EL4 IL-2. J Biol Chem 1996; 271: 13175-83.
11. Nocerino E, Amato M, Izzo AA. Cannabis and cannabinoid receptors. Fitotherapia 2000; 711: S6-12.
12. Yuan M, Kiertscher SM, Cheng Q, Zoumalan RM, Tashkin DP, Roth MD. Delta 9-tetrahydrocannabinol regulates TH1/TH2 cytokine balance in activated human T-cells. J Neuroimmunol 2002; 133: 124-31.
13. Kathuria S, Gaetani S, Valino F, Duranti A, Tontini A, Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
14. Nong L, Newton C, Friedman H, Klein TW. CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Adv Exp Med Biol 2001; 493: 229-33.
15. Di Marzo VT, Bisogno L, De Petrocellis D, Melck BR, Martin D. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr Med Chem 1999; 6: 721-31.
16. Zhu LX, Sharma M, Stolina B, Gardner MD, Roth DP, Tashkin SM, Dubinett S. Δ-9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000; 165: 373-76.
17. Maccarrone M, Finazzi-Agro A. Endocannabinoids and their actions. Vitam Horm 2002; 65: 225-55.
18. Eid MA, Lewis RW, Kumar MV. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor a-related apoptosis-inducing ligand (TRAIL). Mol Cancer Ther 2002; 1: 831-40.
19. Fiona BP. Medical statistics. Edinburgh, London and New York: Churchill Livingstone, 1984: 75-84.
20. Cabral GA, Stinnett, AL, Bailey, J, Ali SF, Paule, MG Scallet, AC, Slikker W. Chronic marijuana smoke alters alveolar macrophage morphology and protein expression. Pharmacol Biochem Behav 1991; 40: 643-49.
21. Bhargava HN, House RV, Thorat SN, Thomas PT. Cellular immune function in mice tolerant to or abstinent from 1-trans-delta 9-tetrahydrocannabinol. Pharmacology 1996; 52: 271-82.
22. Massi P, Sacerdote P, Ponti W, Fuzio D, Manfredi B, Vigano D, Parolaro D. Immune function alteration in mice tolerant to delta 9 tetrahydrocannabinol: Functional and biochemical parameters. J Neuroimmunol 1996; 92: 60-66.
23. Denis P. Pharmacology and toxicity of cannabis. In Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. London: Macmillan Press, 1997: 64.
24. Tashkin DR, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 2002; 42: 71s-81s.
25. Ihenetu K, Molleman A, Parsons M, Whelan C. Pharmacological characterization of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Eur J Pharmacol 2003; 464: 207-15.
26. Tong-Rong Jan, Gautham K, Roa E, Norbert E. Cannabinol enhancement of interlukin-2 (IL-2) expression by T-cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol Pharm 2002; 61: 446-54.
27. Klein TW, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998; 19: 373-81.
28. Ongradi J, Specters S, Horvath A, Friendman H. Additive effect of marihuana and retrovirus in the anergy of natural killer cells in mice. Orv Hetil 1999; 140: 81-84.
29. Massi P, Fuzio D, Vigano D, Sacerdote P, Parolaro D. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol 2000; 387: 343-47.
30. Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998; 83: 116-23.
31. Stites DP, Stobo JD, Wells JV. Basic and clinical immunology. 6th ed, Norwalk, CA: Appleton and Lango, 1987: 114-23.
32. Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Carroll MC. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996; 157: 549-56.
33. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 179: 181-86.
34. Howlett AC, Julius L. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002; 68-69: 619-31.
35. Ueda, N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat. 2002; 68-69: 521-43.
36. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci 2001; 16: 9371-76.
37. Schwarz H, Blanco FJ, Lotz M. Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 1994; 55: 107-15.